Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-positive individuals aged 20 year or more, and~* Those who had completed at least a primary series of HAV vaccination (i.e. two doses of HAVRIX 1440, 6-12 months apart; or two doses of Vaqta 50U, 6-18 months apart), and~* Those who failed to achieve serological response at least 4 weeks after the last dose of primary HAV vaccination.~Exclusion Criteria:~* Patients who have acute illness or acute hepatitis A related symptoms (fever, malaise, nausea, vomiting, abdominal discomfort, and jaundice) within 30 days.~* Patients who have positive anti-HAV IgM within 30 days.~* Patients who were taking immunosuppressant or steroid.~* Patients who were allergic to HAV vaccine.~* Incompetent or unconsented patients.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1-dose group (Type: ACTIVE_COMPARATOR): Provide 1 booster dose of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
- 2-dose group (Type: EXPERIMENTAL): Provide 2 booster doses of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).